ArticleCancer innovation2023
Correction to "Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first-line options for HER2-positive relapsed or metastatic breast cancer".
PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.